All In Biotech

Investigational drug · Phase 3

Cadonilimab

Also called: AK104

Not approved by FDA. In 31 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

31

27 still active

All registered trials

174

Any phase or sponsor naming "Cadonilimab"

First trial start

2021

Aug 23, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Cadonilimab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hepatocellular Carcinoma
  • Gastric / Gastroesophageal Junction Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Cervical Cancer
  • Advanced Non-small-cell Lung Cancer
  • Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
  • Pancreatic Cancer
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Renal Cell Carcinoma, Clear Cell
  • Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Approved drugs for the same conditions: Small cell lung cancer · Pancreatic cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Cervical cancer · Oncology · Kidney and urology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Cadonilimab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 189 on PubMed

Also in development for Hepatocellular Carcinoma

  • IvonescimabAK112, SMT112Phase 349 trials

    Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors

  • RilvegostomigAZD2936Phase 325 trials

    AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer

  • SintilimabIBI308Phase 321 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma

  • VolrustomigMEDI5752Phase 313 trials

    AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer

  • PF-08634404SSGJ-707Phase 312 trials

    Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • TiragolumabMTIG7192A, RO7092284Phase 311 trials

    Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer

  • ZG005Phase 311 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.